Key Details
Price
$0.72Annual ROE
-286.47%Beta
0.85Events Calendar
Next earnings date:
Mar 05, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Mar 05, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Gossamer Bio (GOSS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
The heavy selling pressure might have exhausted for Gossamer Bio (GOSS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Gossamer Bio (GOSS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.21 per share a year ago.
Penny stocks are an interesting category. While they have the potential to produce significant long-run gains, you should never bet money on these stocks that you can't afford to lose.
Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and systemic absorption issues, unlike seralutinib, which targets key disease pathways effectively. Tyvaso DPI's success in PH-ILD highlights the unmet need, with Gossamer planning a Phase 3 trial for seralutinib in mid-2025.
Gossamer Bio (GOSS) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.45 per share a year ago.
Oppenheimer initiated coverage on Gossamer Bio Inc GOSS, a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.
Gossamer Bio announced a partnership with Chiesi Group to develop and market its drug seralutinib for various conditions related to blood pressure.
Gossamer Bio, Inc. (GOSS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GOSS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
FAQ
- What is the primary business of Gossamer Bio?
- What is the ticker symbol for Gossamer Bio?
- Does Gossamer Bio pay dividends?
- What sector is Gossamer Bio in?
- What industry is Gossamer Bio in?
- What country is Gossamer Bio based in?
- When did Gossamer Bio go public?
- Is Gossamer Bio in the S&P 500?
- Is Gossamer Bio in the NASDAQ 100?
- Is Gossamer Bio in the Dow Jones?
- When was Gossamer Bio's last earnings report?
- When does Gossamer Bio report earnings?
- Should I buy Gossamer Bio stock now?